Lung transplantation is the definitive therapy for many end-stage pulmonary diseases. However, the long-term survival of the lung transplant recipient is limited by chronic rejection known as obliterative bronchiolitis (OB, aka bronchiolitis obliterans syndrome [BOS] ) (1) . In fact, OB largely accounts for the 50% five-year survival rate after lung transplantation, which is the worst of all solid organ allografts (1) . The mechanisms leading to OB continue to be an area of intensive investigation, and studies have revealed that immune responses to the donor (alloimmunity) as well as exposure of autoantigens may participate in the rejection response (reviewed in ref. 2) . The convergent result of these injurious activities is the development of a fibroproliferative process resulting in small airway occlusion, which is the pathologic hallmark of OB.
OB stems from hypoxia
Implicit in the term chronic rejection is the idea that immune mechanisms are likely to predominate in OB. However, even prior to immune activation, the lung may be at risk for OB due to airway hypoxia resulting from transplant-related microvasculature interruption. The lung has three vascular supplies, the pulmonary arteries, the pulmonary veins, and the bronchial artery, and is the only solid organ for which allograft does not involve direct systemic arterial reconnection at the time of surgery. The pulmonary arterial/venous circulation is restored in the transplanted lung. However, the bronchial artery, the only source of fully oxygenated blood under systemic arterial pressure, is not reanastomosed after transplantation due to the significant technical complexities associated with this procedure.
The lack of an intact bronchial artery circulation leads to impaired microcirculation, suggesting that prolonged airway hypoxia contributes to OB. In fact, previous studies from the Nicolls group have confirmed that airway epithelial hypoxia occurs following clinical lung transplantation (3), and other researchers have reported that the loss of the microvasculature in small airways precedes OB (4, 5) . Hypoxia, a key adverse effect of losing the vascular supply, may induce profound changes in airway epithelium. One of these effects could be the induction of epithelial mesenchymal transition (EMT), a process implicated in fibrogenesis in many organs, including the lung (6) . Indeed, studies from the laboratory of Jacob Sznajder demonstrated that both moderate and severe hypoxia induced EMT (6) . These findings have direct relevance to lung transplantation, since recent studies have detected EMT in OB lesions (7) (8) (9) .
Recent studies strongly suggest that hypoxia may lower the threshold to induce adaptive immune responses known to have key roles in acute lung transplant rejection. Due to the presence of bronchus-associated lymphoid tissue, interstitial and interepithelial dendritic cells, a full complement of lymphocytes, and macrophages, the lung is uniquely able to mount adaptive immune responses in the absence of any secondary lymphoid organs (10, 11) . Indeed, in essence, the lung is a lymph node with alveoli (2) . What is the relationship of immunity to chronic hypoxia and rejection in the transplanted lung? Recent studies indicate that hypoxia may augment immune activation (12) and that alloimmune activation occurs within the transplanted lung (10) . For example, hypoxia induces the activation of dendritic cells that stimulate alloimmunity, produce proinflammatory cytokines, and activate Th17 cells that produce IL-17 (13, 14) . In addition, production of IL-17 is strongly correlated with OB (15) . Collectively, these studies suggest that hypoxia may lead to augmented allo- and autoimmunity injury that further predisposes to fibrogenesis. It is well documented that calcineurin inhibitors (CNI), the mainstay of posttransplant immunosuppressive therapy, may also be fibrogenic. Therefore, delivery of these agents, either systemically or via the inhaled route, is likely not to prevent OB, but instead could actually contribute to fibrogenesis in part due to airway hypoxia that results from a lack of an intact and robust airway microvasculature. Indeed, widespread CNI use could help to explain why 75% of lung transplant recipients develop OB (1).
A new direction for prevention?
If the loss of microvasculature after lung transplantation results in hypoxia leading to airway fibrosis, then normoxia via microvascular repair should prevent fibrosis. Indeed, data derived from a unique preclinical model reported by Jiang et al. in the current issue of the JCI fully support this hypothesis (16) . This work is an extension of a prior study from the same group and reported previously in the JCI (17) . Utilizing a mouse model of orthotopic airway allograft transplantation, the researchers found that restoration of airway microvasculature via local overexpression of HIF-1α not only resulted in normoxic conditions, but also prevented airway fibrosis. Moreover, the authors show that endogenous HIF-1α expression was limited to donor, and not recipient, endothelial cells (16) . Although constitutive HIF-1α expression occurred following airway transplantation, it was not sufficient to prevent the fibrotic response. Notably, vascular bed development was HIF-1α dependent, since revascularization was profoundly limited in allografts genetically deficient in HIF-1α. In addition, the rate of chronic rejection was accelerated markedly in HIF-1α-deficient and wild-type grafts, whereas overexpressing HIF-1α prevented fibrosis and delayed the onset of OB. These data are consistent with a study from Belperio et al., who reported angiogenesis occurring after loss of the microvasculature actually facilitated fibrosis in models of obliterative airway disease (18) . Collectively, these studies demonstrate that not only is hypoxia a major risk factor for fibrosis that characterizes chronic rejection, but also that a dysfunctional vascular bed with associated hypoxia exacerbates the fibrotic response.
Why HIF-1?
There are many proangiogenic mediators, so one must question the reasoning behind a specific focus on HIF-1. The induction of virtually all known angiogenic growth factors is HIF-1α dependent, and hypoxia is a potent stimulator for HIF-1α (reviewed in ref. 19 ). There are many clinical implications of the current study. Immune modulation after transplantation has been and continues to be the primary focus of strategies to prevent OB; however, there are no effective immunosuppressive therapies for chronic rejection. The study from Jiang et al. provides hope in this regard. HIF-1α-induced revascularization slowed the rate of chronic rejection despite the presence of alloreactive T cells that are known to mediate the rejection response. Furthermore, this protective effect was augmented when the immune system was suppressed via costimulatory blockade. These data also suggest that hypoxia induced by a dysregulated vascular supply likely predisposes the airway to alloimmune-induced injury (16) . Accordingly, restoration of a robust airway microvasculature in the presence of appropriate immunosuppression might prevent chronic rejection. In other words, it is interesting to speculate that the inability to treat OB with currently utilized immunosuppressive regimens could be in part due to airway hypoxia that results from an aberrant airway microvasculature.
Data from the current report strongly suggest that airway microvasculature preservation should be a desired outcome immediately after transplantation and during acute rejection episodes when the microvascular bed is under immune attack. Unfortunately, preservation of the airway microvasculature by donor-recipient bronchial artery anastomosis at the time of transplantation may not prevent OB, since acute rejection-induced microvascular loss could occur virtually any time after transplant. It is easy to surmise from the data presented by Jiang et al. that HIF-1α could be a potential therapeutic in clinical lung transplantation to preserve the microvasculature, thereby preventing tissue hypoxia/fibrosis. Pharmacologic agents that could be used in this regard do exist; desferoxamine and CoCl 2 have been reported to induce HIF-1 expression in animal models of ischemic injury (19) . However, toxicities and nonspecific actions would preclude the clinical use of such agents in lung transplantation. Similar to the current study, HIF-1α gene therapy has been efficacious in restoring vascular integrity in other preclinical models (20) , but the potential limitations of adenoviralmediated gene therapy in the clinical setting have been well documented.
Future directions
What is the future of determining the effects of airway microvasculature preservation and repair in the transplanted lung on clinical OB? I envision a two-step process. The first step will be to conduct randomized trials of bronchial artery anastomosis at the time of lung transplantation followed by an assessment of OB. If bronchial anastomosis fails to prevent the development of OB, it is possible that acute rejection-induced microvasculature loss is inevitable after transplantation. If that is the case, the second step will be to develop strategies to deliver HIF-1α to sites of active acute rejection in the presence of augmented immunosuppression to determine whether OB may be prevented. Robust animal models will facilitate the development of new therapeutics. Although a mouse model of orthotopic lung transplantation that develops OB has been developed recently (21) , technical limitations preclude the use of this model to study bronchial artery reanastomosis. However, such a model could be the platform for studying novel approaches for delivery of HIF-1α to the transplanted lung. Finally, studies of OB have focused almost exclusively on various aspects of immune regulation. The current report from Jiang et al. identifies a role for vascular biology in chronic rejection and is a major step forward in understanding the nonimmune mechanisms at play in the pathogenesis of this lethal disease. Accordingly, this report is also a clarion call for continued in-depth investigations into the nonimmune pathways that contribute to OB to identify novel targets for therapeutic intervention.
